Point72 Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Point72 Asset Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,100,994	Closed	-$4.13M	–	1916
2022 Q3	$4.13M	Buy	1,100,994 +765,886	+229%	+$3.54M	0.02%	774
2022 Q2	$1.99M	Sell	335,108 -6,577	-2%	-$37.1K	0.01%	935
2022 Q1	$2.16M	Hold	341,685	–	–	0.01%	865
2021 Q4	$1.34M	Hold	341,685	–	–	0.01%	871
2021 Q3	$1.65M	Buy	341,685 +132,122	+63%	+$689K	0.01%	798
2021 Q2	$1.34M	Buy	+209,563	New	+$1.38M	0.01%	775

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Point72 Asset Management's MACK Position: Q4 2022 in Review

Point72 Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2022, closing a stake of 1,100,994 shares — an estimated $4.13M sold.

Point72 Asset Management first reported a position in MACK in Q2 2021 and held it in 6 quarters. The position peaked at $4.13M in Q3 2022. 47 funds tracked by Wall St. Rank hold MACK as of Q4 2022.

Point72 Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Point72 Asset Management sold 1,100,994 Merrimack Pharmaceuticals, Inc. shares in Q4 2022, an estimated $4.13M.
Point72 Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2021 and held it in 6 quarters.
Point72 Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $4.13M in Q3 2022.
47 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2022.

Based on Point72 Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.